Universität zu Köln

Svacina, Martin K. R., Roeth, Philip, Bobylev, Ilja, Sprenger, Alina, Zhang, Gang, Sheikh, Kazim A. and Lehmann, Helmar C. (2019). Changes of Serum IgG Dimer Levels after Treatment with IVIg in Guillain-Barre Syndrome. J. Neuroimmune Pharm., 14 (4). S. 642 - 649. NEW YORK: SPRINGER. ISSN 1557-1904

Full text not available from this repository.

Abstract

Intravenous immunoglobulins (IVIg) are standard treatment for Guillain-Barre syndrome (GBS). Their exact mechanisms of action are versatile and not fully understood. One possible mechanism is neutralization of circulating autoantibodies via binding to anti- idiotypic antibodies forming idiotype-anti-idiotype dimeric IgG immune complexes. To examine the role of immune complex formation as mechanism of action for IVIg in GBS, 34 C57Bl/6 mice were either treated with anti-ganglioside antibodies and IVIg or IVIg and PBS alone, whereas eight additional mice were treated either with anti-ganglioside autoantibodies and IVIg or anti-ganglioside autoantibodies alone. Subsequently IgG dimer formation was assessed by high performance liquid chromatography (HPLC) and enzyme- linked immunosorbent assay (ELISA). In addition, IgG dimer formation was measured in sera of eight GBS patients who were treated with IVIg. In mice, a significant increase of dimeric IgG after administration of anti-ganglioside antibodies and IVIg could be observed. Re-monomerized IgG dimers showed immunoreactivity against gangliosides and serum immunoreactivity was significantly reduced after IVIg infusion. Likewise also in GBS patients, IgG dimer formation could be detected after IVIg treatment. Our data indicate that dimeric IgG immune complexes contain anti-idiotypic antibodies and provide proof of concept that IVIg treatment in GBS results in measurable amounts of IgG dimers. Larger patient cohorts are needed to evaluate serum IgG dimer increase as a possible marker for treatment response in GBS.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Svacina, Martin K. R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Roeth, Philip UNSPECIFIED UNSPECIFIED UNSPECIFIED Bobylev, Ilja UNSPECIFIED UNSPECIFIED UNSPECIFIED Sprenger, Alina UNSPECIFIED UNSPECIFIED UNSPECIFIED Zhang, Gang UNSPECIFIED UNSPECIFIED UNSPECIFIED Sheikh, Kazim A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Lehmann, Helmar C. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-125179
DOI:	10.1007/s11481-019-09871-0
Journal or Publication Title:	J. Neuroimmune Pharm.
Volume:	14
Number:	4
Page Range:	S. 642 - 649
Date:	2019
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1557-1904
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS; THERAPEUTIC-EFFICACY; IMMUNE GLOBULIN; COMPLEX Multiple languages Neurosciences; Pharmacology & Pharmacy Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/12517